Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ubiquitin pathway modulators for treating pancreatitis

Award Number: R43DK138712
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2025
AWARD TERMINATION DATE: 02/05/2026

Group Awards By:

View Award Description

Ubiquitin pathway modulators for treating pancreatitis - New approaches are needed to treat acute and chronic pancreatitis which is a major health problem in the US. One novel approach is to promote mitochondrial health to protect pancreas from damages caused by various stressors. We have identified important roles for mitophagy in resistance to pancreatitis. These new findings, in the setting of the urgent medical need for new approaches to treat pancreatitis, led to this new SBIR application to fully leverage prior discoveries. Ubiquitin proteasome system (UPS) is a key regulator of autophagic clearance of damaged mitochondria. As such, activation of ubiquitin pathway enzyme critically involved in promoting mitochondrial health is expected to have therapeutic effects. Pogenra’s UbiProTM drug discovery platform was employed to discover novel, potent and selective activators of UPS enzymes. We demonstrated that UPS activator inhibited pancreatitis in vivo. In this Phase I grant, we propose to evaluate these novel molecules for their efficacy in cellular and animal models of acute and chronic pancreatitis and perform mechanism of action studies. The ultimate commercial goal of this project is the development of small molecule UPS activators as novel drugs that could treat pancreatitis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	PROGENRA INC	271A GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	2/5/2026	TERMINATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	PROGENRA INC	271A GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	10/30/2024	NEW	$0
2025	2024	PROGENRA INC	271A GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	12/19/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $269,622 )
2024	2024	PROGENRA INC	271A GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/19/2024	NEW	$269,622
														Subtotal = $269,622

Grand Total All Awards = $269,622

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ubiquitin pathway modulators for treating pancreatitis

Award Number: R43DK138712

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2025

AWARD TERMINATION DATE: 02/05/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer